Chembio Diagnostics Inc (NASDAQ:CEMI) disclosed a collaboration with Stony Brook Medicine to identify coronavirus survivors.
The Hauppage, New York-based company reported Thursday its DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies has been selected for use in a Stony Brook effort to recruit patients who have recovered from COVID-19 infection.
The study is intended to determine if convalescent blood plasma, the plasma from people who have recovered from COVID-19, can help treat hospitalized patients with active COVID-19 infection. In early April, Stony Brook University Hospital received FDA approval to offer convalescent blood plasma treatment to its patients through a randomized, controlled study and is expected to enroll up to 500 patients from the Long Island area.
The Chembio DPP COVID-19 test is being used to confirm that patients were infected with COVID-19 and now have adequate levels of IgG antibodies to make them eligible to donate convalescent plasma.
Said Chief Technology Officer Jayan Esfandiaii, "Our collaboration with Stony Brook Medicine on this important study represents the next step in our COVID-19 initiative, which includes our earlier receipt of authorization to market and sell the DPP COVID-19 IgM and IgG assay system in the United States through the FDA notification process.
"We are pleased that our unique and proprietary DPP technology, which can separately and simultaneously detect and measure IgM and IgG antibodies specific to COVID-19, is the assay of choice for Stony Brook Medicine."
Shares gained $1.28, or 15.8%, to $9.36.
Related Stories
